Emancipated' biotechs offer new drugs for neurodegeneration

Article Abstract:

Six new drugs for the rare neurodegenerative disease amyotropic lateral sclerosis (ALS) are poised to enter clinical traits. Of those, two drugs ritonavir and hydroxyurea are products of a tiny, young nonprofit biotechnology company. Nonprofit biotechs focus on accelerating drug discovery for rare or poorly understood diseases, traditionally deemed financially unattractive by large pharmaceutical companies.

Drugs, Care and treatment, Biotechnology industry, Biotechnology industries, Nervous system, Pharmaceutical research, Neurodegenerative diseases

---

Spirituality's rising role in medicine stirs debate

Article Abstract:

Scientists believe that a subjective concept like spirituality cannot and should not be linked to science. Researchers have struggled to differentiate between the health effects of faith and other variables such as behavioral risk factors and socioeconomic issues.

United States, Health aspects, Analysis, Beliefs, opinions and attitudes, Spirituality

---

Technologies that deliver

Article Abstract:

Scientist are roiling new ways to deliver a drug directly to its target. But there are many stakes because a therapeutic agent often thwarts disease only when it is delivered actually.

Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Drug Delivery Systems, Technology application

Similar abstracts:

• Abstracts: Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration . Polyglutamine neurodegeneration: minding your Ps and Qs
• Abstracts: A prion protein epitope selective for the pathologically misfolded conformation. The controversial protein-only hypothesis of prion propagation
• Abstracts: Paul Epstein. Paging all doctors. Kari Stefansson

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.